Uncategorized
Alternative therapies in development for DME
KOLOA, Hawaii — A number of treatment regimens in development may prove superior to current standards of care for center-involved diabetic macular edema, according to a speaker here. Multiple pathways are being explored to enhance treatment of diabetic macular edema, whether alone or in combination with anti-VEGF for treatment of DME. Agents include PF-655, AKB-9778 and iCo-007, Quan D. Nguyen, MD, MSc, said at Retina 2014. PF-655 is a synthetic chemically modified siRNA that targets the RTP801 gene, which is expressed in human age-related macular degeneration.